What is Leerink Partnrs’ Forecast for TENX FY2024 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at Leerink Partnrs issued their FY2024 EPS estimates for Tenax Therapeutics in a research note issued to investors on Thursday, October 24th. Leerink Partnrs analyst D. Risinger anticipates that the specialty pharmaceutical company will post earnings per share of ($6.20) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($6.62) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ FY2025 earnings at ($8.30) EPS, FY2026 earnings at ($3.90) EPS, FY2027 earnings at ($4.10) EPS and FY2028 earnings at ($2.70) EPS.

A number of other equities research analysts also recently commented on TENX. Guggenheim started coverage on shares of Tenax Therapeutics in a research report on Monday, October 14th. They issued a “buy” rating and a $16.00 target price for the company. StockNews.com started coverage on shares of Tenax Therapeutics in a research report on Thursday, September 26th. They issued a “sell” rating for the company. Leerink Partners started coverage on shares of Tenax Therapeutics in a research report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 target price for the company. Finally, William Blair started coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $170.67.

Tenax Therapeutics Price Performance

Shares of TENX opened at $4.59 on Monday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $61.20. The firm has a 50 day moving average of $3.81 and a 200 day moving average of $3.60.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share for the quarter, beating the consensus estimate of ($1.99) by $0.16.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.